Cymbiotika Secures $55 Million in Debt and Equity Funding to Accelerate Global Wellness Expansion

Cymbiotika LLC, a San Diego–based wellness and supplement company known for its focus on bioavailability, clean ingredients, and science-backed formulations, has secured significant funding that underscores its rapid growth and expanding presence in the global wellness market. The company has attracted both strategic debt financing and high-profile equity backing, providing capital to scale operations, expand retail distribution, and strengthen its infrastructure as demand for its products continues to grow.

In October 2024, Cymbiotika announced that it had secured $30 million in debt financing led by RevTek Capital, a growth-focused capital provider specializing in structured debt solutions for high-growth companies. The financing was designed to support Cymbiotika’s next phase of expansion, including investments in automation, supply chain optimization, and infrastructure improvements. The company also indicated that the capital would be used to accelerate its retail strategy, strengthen its digital and omnichannel capabilities, and support expansion into new geographic markets, including Canada.

The debt facility marked a strategic move for Cymbiotika, allowing it to fuel growth while maintaining operational control. Company leadership emphasized that the structure of the financing aligned with its long-term vision of sustainable scaling rather than short-term dilution. By strengthening its balance sheet, Cymbiotika positioned itself to meet increasing consumer demand while continuing to innovate across its supplement portfolio.

Building on that momentum, Cymbiotika took a major step into equity financing in November 2025, when it raised $25 million in a seed funding round. The round was notable not only for its size, but also for the profile of its investors. The raise came after years of bootstrapped growth, during which the company reportedly reached approximately $150 million in annual revenue, drawing attention from investors outside traditional venture capital circles.

The seed round was led by hospitality entrepreneur David Grutman and included a diverse group of celebrity and business investors. Participants included musician The Weeknd, artist Post Malone, entrepreneur and television personality Daymond John, DJ and producer Steve Aoki, songwriter and producer Ryan Tedder, and electronic music artist Peggy Gou. The involvement of these high-profile figures reflects Cymbiotika’s growing cultural influence and its appeal as a lifestyle and wellness brand.

The company has indicated that the equity capital will be used to further expand its retail footprint, deepen brand awareness, and support continued product development. Cymbiotika has already established a strong direct-to-consumer presence and has been expanding into brick-and-mortar retail, with plans to increase accessibility through national and international partners. The funding also supports investments in research and development, ensuring that new products align with the company’s emphasis on transparency, quality, and advanced delivery systems.

Together, the $30 million debt facility and the $25 million seed round highlight Cymbiotika’s multifaceted approach to financing. By combining structured debt with strategic equity from culturally influential investors, the company has assembled the resources needed to scale while reinforcing its brand identity. As the wellness and supplement industry continues to grow and evolve, Cymbiotika’s funding milestones position it as a prominent player with the capital and visibility to compete on a global stage.